Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11163060 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL11163056 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL177205 | 0.83 | — | — | |
| SCHEMBL12476221 | 0.83 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL13804069 | 0.82 | CHRM2 (0.36) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL21291237 | 0.82 | SERPINE1 (0.31) | — | |
| SCHEMBL19840159 | 0.82 | CHRM2 (0.36) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL28780475 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL28770241 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL28064630 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-12-22 | — | — | US | disclosed |
| WO-2019161213-A1 | TRIALKYNE LINKING AGENTS AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402947-A1 | Trialkyne Linking Agents and Methods of Use | DCLRE1A, DTYMK, RTCB | CHRM2 4817/4885CHRM1 4786/4885CHRM4 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.